Novartis AG vs Paycom Software Inc — how do they compare? Novartis AG trades at $137.61 (market cap $262.64B), while Paycom Software Inc trades at $214.7 (market cap $9.88B). The key difference: Novartis AG is far larger — about 26.6× Paycom Software Inc's market cap, and Novartis AG pays the higher dividend (3.44%). Which is the better fit depends on your goals.
| NVS | PAYC | |
|---|---|---|
Market Cap | $262.64B | $9.88B |
Sector | Health | Technology |
52-Week High | $168.62 | $240.52 |
52-Week Low | $121.80 | $113.59 |
Enterprise Value | $303.97B | $10.66B |
Dividend Yield | 3.44% | 0.68% |
Signals from Pluang's Aura AI — not financial advice
Novartis (NVS) is trading at $137.70, down 13.93% following significant clinical trial setbacks for del-desiran and pelacarsen. The stock shows bearish technical signals with support at $133-$136 and resistance at $140-$143. Fundamentally, the company maintains strong profitability with 74.74% gross margins and 22.5% net income margins, though recent pipeline failures have overshadowed solid financial performance.
While Novartis maintains strong financial fundamentals and reiterated 2025-2030 growth guidance, the recent clinical trial failures create near-term uncertainty. The stock faces pressure from pipeline setbacks but offers value at current levels for long-term investors willing to weather development risks. Analyst consensus remains cautious with 68% hold ratings.
Paycom Software (PAYC) trades at $219.16, down 5.4% today but maintains strong fundamentals with consistent earnings beats and robust profitability. The stock shows a bullish technical signal despite recent weakness, supported by positive analyst sentiment and institutional accumulation. Recent Q2 2026 results exceeded expectations with EPS of $2.78 beating estimates of $2.38, driving management's raised full-year guidance.
Outlook remains positive with a consensus price target of $231.70 offering 5.7% upside potential. Key opportunities include sustained revenue growth and expanding margins, while risks involve competitive pressures and market volatility. The company's strong cash flow generation and shareholder returns through dividends and buybacks support long-term value creation.
Trailing returns across standard periods
Latest headlines on both assets
Novartis develops and manufactures healthcare products through two segments: Innovative Medicines and Sandoz. It generates the vast majority of its revenue from Innovative Medicines segment consisting global business franchises in oncology, ophthalmology, neuroscience, immunology, respiratory, cardio-metabolic, and established medicines. The company sells its products globally, with the United States representing close to one third of total revenue.
Read more on NVS →Paycom is a fast-growing provider of payroll and human capital management, or HCM, software primarily targeting clients with 50-10,000 employees in the United States. Paycom was established in 1998 and services about 18,000 clients as of 2021, based on parent company grouping. Alongside its core payroll software, Paycom offers various HCM add-on modules, including time and attendance, talent management, and benefits administration.
Read more on PAYC →